ARYA - ARYA Sciences Acquisition Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
15.15
+15.15 (+-3.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.00
Open15.37
Bid0.00 x 1800
Ask0.00 x 1100
Day's Range14.72 - 15.37
52 Week Range9.84 - 17.48
Volume287,734
Avg. Volume324,628
Market Cap272.227M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-47% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics
    Business Wire

    Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

    Arya Sciences Acquisition Corp. (NASDAQ: ARYA or "Arya"), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH ("Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that its respective shareholders approved the business combination between Arya and Immatics announced on March 17, 2020. None of Arya’s shareholders redeemed their shares in connection with the ARYA shareholder approval. The respective boards of directors of both Arya and Immatics had previously approved the business combination.

  • ACCESSWIRE

    ACT NOW: Monteverde & Associates Is Investigating the Merger

    NEW YORK, NY / ACCESSWIRE / June 17, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Arya Sciences Acquisition Corp. - ARYA
    PR Newswire

    STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Arya Sciences Acquisition Corp. - ARYA

    Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Arya Sciences Acquisition Corp. ("Arya Sciences" or the "Company") (NasdaqGS: ARYA) relating its combination with Immatics B.V., a Netherlands private limited company. Under the terms of the agreement, each outstanding share of Arya common stock, will be automatically exchanged for one share of the newly formed company, Immatics N.V.